首页 > 最新文献

Gastroenterologia y hepatologia最新文献

英文 中文
Screening for advanced liver disease incorporating the use of transitional elastography in primary care. 筛查晚期肝病,在初级保健中使用过渡弹性成像技术。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-06 DOI: 10.1016/j.gastrohep.2024.502242
Mar Noguerol Álvarez, Mª Paz Valer López Fando, Carolina Torrijos Bravo, Mª Carmen Gómez Ortiz, Belén Piqueras Alcohol, Antonio Guardiola Arévalo, Gema De la Poza Gómez, Zahara Pascual García, Sandra Rey Rodríguez, Raquel Iglesias Sigüenza, Esther Ledesma Estévez, Susana Parra Román, María Gómez Suárez, Angela Pérez San Juan, Miriam Ruiz Romero, Laura Martínez Vega, Beatriz López Uriarte, Francisco Góngora Maldonado, Blanca Martín Porras, Pilar Serrano Gismero, Elvira Rubio Benito, Gloria Viñas Fernández, Mª José Rojas Giraldo, Ana Mª Hernández Sánchez, María Alonso Ovies, Gema María Saiz Ladera, Nuria Martín Peña, Jesús Fernández Horcajuelo, Victoria Llinares Gómez, José Francisco Sánchez Mateos, Elena Polentinos Castro, Ricardo Rodríguez Barrientos, Manuel Carbajo Ariza, Greta Amat Baeza, Fernando Bermejo San José

Objectives: To describe the proportion of patients with liver fibrosis in at-risk populations in primary care (PC). To know the agreement between FIB-4 and transitional elastography (TE), interobserver agreement between PC and hospital care (HC) in TE, and associated risk Factors (RF).

Methods: Observational, descriptive, cross-sectional study in ≥16 years of age with RF for chronic liver disease. Sex and age, RF (alteration of liver tests (LT), metabolic syndrome, diabetes, obesity, alcohol consumption, hepatic steatosis), and FIB-4, controlled attenuation parameter and TE in PC and in HC, were collected. According to a consensus algorithm, vibration-controlled TE was performed in PC in patients with FIB-4≥1,3, and those with measurement≥8 kPa were referred to HC.

Results: 326 patients were studied. 71% were not referred to HC, due to liver stiffness<8 kPa. 83 of the 95 derivations did TE in HC. 45(54%) had TE≥8, and 25(30%)≥12. The proportion of patients with stiffness≥8 kPa was 13,8%(45/326) and ≥12 kPa, 7,6%(25/326). The predictive values ​​of the FIB-4 were low. The interobserver correlation coefficient between TE in PC and HC was 0,433. Variables associated with TE≥8 in PC: LT alteration, diabetes and steatosis. With TE≥12: LT alteration, diabetes and obesity.

Predictor variables: LT alteration and obesity.

Conclusions: The study supports the sequential performance of serum indices and TE as a screening for fibrosis in the at-risk population in PC, which allows a reduction in the percentage of patients referred to AH, and a better stratification of risk patients.

目的描述基层医疗机构(PC)高危人群中肝脏纤维化患者的比例。了解 FIB-4 和过渡弹性成像(TE)之间的一致性、PC 和医院护理(HC)在过渡弹性成像中的观察者间一致性以及相关风险因素(RF):观察性、描述性、横断面研究,对象为年龄≥16 岁的慢性肝病 RF 患者。研究收集了性别和年龄、RF(肝脏检查(LT)改变、代谢综合征、糖尿病、肥胖、饮酒、肝脏脂肪变性)、FIB-4、PC 和 HC 的受控衰减参数和 TE。根据共识算法,FIB-4≥1,3的患者在PC中进行振动控制TE,测量值≥8 kPa的患者转至HC:研究了 326 名患者。71%的患者因肝僵化而未被转至肝脏疾病中心:LT改变和肥胖:该研究支持将血清指数和 TE 作为 PC 高危人群肝纤维化筛查的先后顺序,从而降低转诊至 AH 的患者比例,并更好地对高危患者进行分层。
{"title":"Screening for advanced liver disease incorporating the use of transitional elastography in primary care.","authors":"Mar Noguerol Álvarez, Mª Paz Valer López Fando, Carolina Torrijos Bravo, Mª Carmen Gómez Ortiz, Belén Piqueras Alcohol, Antonio Guardiola Arévalo, Gema De la Poza Gómez, Zahara Pascual García, Sandra Rey Rodríguez, Raquel Iglesias Sigüenza, Esther Ledesma Estévez, Susana Parra Román, María Gómez Suárez, Angela Pérez San Juan, Miriam Ruiz Romero, Laura Martínez Vega, Beatriz López Uriarte, Francisco Góngora Maldonado, Blanca Martín Porras, Pilar Serrano Gismero, Elvira Rubio Benito, Gloria Viñas Fernández, Mª José Rojas Giraldo, Ana Mª Hernández Sánchez, María Alonso Ovies, Gema María Saiz Ladera, Nuria Martín Peña, Jesús Fernández Horcajuelo, Victoria Llinares Gómez, José Francisco Sánchez Mateos, Elena Polentinos Castro, Ricardo Rodríguez Barrientos, Manuel Carbajo Ariza, Greta Amat Baeza, Fernando Bermejo San José","doi":"10.1016/j.gastrohep.2024.502242","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2024.502242","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the proportion of patients with liver fibrosis in at-risk populations in primary care (PC). To know the agreement between FIB-4 and transitional elastography (TE), interobserver agreement between PC and hospital care (HC) in TE, and associated risk Factors (RF).</p><p><strong>Methods: </strong>Observational, descriptive, cross-sectional study in ≥16 years of age with RF for chronic liver disease. Sex and age, RF (alteration of liver tests (LT), metabolic syndrome, diabetes, obesity, alcohol consumption, hepatic steatosis), and FIB-4, controlled attenuation parameter and TE in PC and in HC, were collected. According to a consensus algorithm, vibration-controlled TE was performed in PC in patients with FIB-4≥1,3, and those with measurement≥8 kPa were referred to HC.</p><p><strong>Results: </strong>326 patients were studied. 71% were not referred to HC, due to liver stiffness<8 kPa. 83 of the 95 derivations did TE in HC. 45(54%) had TE≥8, and 25(30%)≥12. The proportion of patients with stiffness≥8 kPa was 13,8%(45/326) and ≥12 kPa, 7,6%(25/326). The predictive values ​​of the FIB-4 were low. The interobserver correlation coefficient between TE in PC and HC was 0,433. Variables associated with TE≥8 in PC: LT alteration, diabetes and steatosis. With TE≥12: LT alteration, diabetes and obesity.</p><p><strong>Predictor variables: </strong>LT alteration and obesity.</p><p><strong>Conclusions: </strong>The study supports the sequential performance of serum indices and TE as a screening for fibrosis in the at-risk population in PC, which allows a reduction in the percentage of patients referred to AH, and a better stratification of risk patients.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax As A Possible Chemopreventive Agent In Adenomatous Polyposis: A Case Report. Venetoclax 可作为腺瘤性息肉病的化学预防药物:病例报告。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-28 DOI: 10.1016/j.gastrohep.2024.502239
Cautar El Maimouni, Maria Daca-Alvarez, Julio Delgado, Maria Pellisé, Francesc Balaguer
{"title":"Venetoclax As A Possible Chemopreventive Agent In Adenomatous Polyposis: A Case Report.","authors":"Cautar El Maimouni, Maria Daca-Alvarez, Julio Delgado, Maria Pellisé, Francesc Balaguer","doi":"10.1016/j.gastrohep.2024.502239","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2024.502239","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142106729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cobblestone Oesophagus: A Rare Form of Severe Oesophagitis in Scleroderma. 鹅卵石食道:硬皮病患者严重食道炎的一种罕见形式。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-26 DOI: 10.1016/j.gastrohep.2024.502238
Raúl Fernández García, Maria Del Carmen Fernández Cano, Eduardo Redondo Cerezo
{"title":"Cobblestone Oesophagus: A Rare Form of Severe Oesophagitis in Scleroderma.","authors":"Raúl Fernández García, Maria Del Carmen Fernández Cano, Eduardo Redondo Cerezo","doi":"10.1016/j.gastrohep.2024.502238","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2024.502238","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Descriptive observational study on the use of virtual reality in patients with inflammatory bowel disease undergoing biological treatment. 关于在接受生物治疗的炎症性肠病患者中使用虚拟现实技术的描述性观察研究。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-22 DOI: 10.1016/j.gastrohep.2024.502236
Raúl José Díaz Molina, Carlos Comesaña Castellar, Joan Crespí Rigo, Catalina Radu Tomsa, Patricia Quesada Bauzá, Isabel Porcel Corra, Pau Sendra Rumbeu, Vanesa Royo Escosa, María Dolores Herrera González, Eva Puchol Segarra, Daniel Ginard Vicens

Background: Virtual reality (VR) is a neurosensory experience in which simulated spaces a person has the sensation of being able to function within them. Some patients with inflammatory bowel disease (IBD) receive intravenous biological treatments in an Adult Day Hospital (ADH) regime. VR has been used in some fields of medicine, demonstrating its usefulness in reducing negative symptoms. However, we do not have any literature showing the applicability in real clinical practice of VR in IBD.

Methods: Descriptive observational pilot study based on an initial cohort of 87 patients that were obtained from the ADH of the IBD Unit. Satisfaction and acceptance of VR through the use of 3D glasses and the reduction of negative symptoms during intravenous biological treatment in patients with IBD in ADH have been assessed.

Results: 43 patients (52.4%) used VR and completed the study. In the comparative analysis of the results of the questionnaires before and after the use of VR, a statistically significant improvement was observed in the patients' view on the ability of VR to achieve a reduction in stress (65% patients improve; p: 0.0021) and pain (VAS, 54% p. improve; p<0.05) during treatment. Likewise, with the applicability of VR in other areas of medicine (53%; p: 0.05) and with the possibility of improving well-being during the stay in the ADH (56%; p: 0.0014). No side effects were reported with the use of the 3D glasses.

Conclusions: VR is a useful complementary tool to improve the stay of patients with IBD on ADH during intravenous treatment.

背景介绍虚拟现实(VR)是一种神经感觉体验,在模拟的空间中,人可以感觉到自己在其中活动。一些炎症性肠病(IBD)患者在成人日间医院(ADH)接受静脉生物治疗。虚拟现实技术已被用于某些医学领域,证明其在减轻负面症状方面非常有用。然而,我们还没有任何文献显示 VR 在 IBD 实际临床实践中的适用性:方法:描述性观察试点研究,基于从肠道疾病科 ADH 获得的 87 名患者的初始队列。研究评估了ADH中的IBD患者通过使用3D眼镜对VR的满意度和接受度,以及在静脉生物治疗过程中减少负面症状的情况:结果:43 名患者(52.4%)使用了 VR 并完成了研究。在对使用 VR 前后的问卷结果进行比较分析时,发现患者对 VR 能够减轻压力(65% 的患者有所改善;P:0.0021)和疼痛(VAS,54% 的患者有所改善;P:0.0021)的看法有了显著改善:VR 是一种有用的辅助工具,可改善接受 ADH 静脉注射治疗的 IBD 患者的住院情况。
{"title":"Descriptive observational study on the use of virtual reality in patients with inflammatory bowel disease undergoing biological treatment.","authors":"Raúl José Díaz Molina, Carlos Comesaña Castellar, Joan Crespí Rigo, Catalina Radu Tomsa, Patricia Quesada Bauzá, Isabel Porcel Corra, Pau Sendra Rumbeu, Vanesa Royo Escosa, María Dolores Herrera González, Eva Puchol Segarra, Daniel Ginard Vicens","doi":"10.1016/j.gastrohep.2024.502236","DOIUrl":"10.1016/j.gastrohep.2024.502236","url":null,"abstract":"<p><strong>Background: </strong>Virtual reality (VR) is a neurosensory experience in which simulated spaces a person has the sensation of being able to function within them. Some patients with inflammatory bowel disease (IBD) receive intravenous biological treatments in an Adult Day Hospital (ADH) regime. VR has been used in some fields of medicine, demonstrating its usefulness in reducing negative symptoms. However, we do not have any literature showing the applicability in real clinical practice of VR in IBD.</p><p><strong>Methods: </strong>Descriptive observational pilot study based on an initial cohort of 87 patients that were obtained from the ADH of the IBD Unit. Satisfaction and acceptance of VR through the use of 3D glasses and the reduction of negative symptoms during intravenous biological treatment in patients with IBD in ADH have been assessed.</p><p><strong>Results: </strong>43 patients (52.4%) used VR and completed the study. In the comparative analysis of the results of the questionnaires before and after the use of VR, a statistically significant improvement was observed in the patients' view on the ability of VR to achieve a reduction in stress (65% patients improve; p: 0.0021) and pain (VAS, 54% p. improve; p<0.05) during treatment. Likewise, with the applicability of VR in other areas of medicine (53%; p: 0.05) and with the possibility of improving well-being during the stay in the ADH (56%; p: 0.0014). No side effects were reported with the use of the 3D glasses.</p><p><strong>Conclusions: </strong>VR is a useful complementary tool to improve the stay of patients with IBD on ADH during intravenous treatment.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tips and tricks for writing a manuscript to publish in a biomedical journal. 撰写在生物医学期刊上发表的稿件的技巧。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-20 DOI: 10.1016/j.gastrohep.2024.502237
Javier P Gisbert, María Chaparro

Science barely exists until it is published. It is only then that the information surpasses the limits of the author and can be shared by the scientific community. Although scientific articles must follow a rigidly defined structure, there is still room to tell a fascinating story, one that clearly conveys the science and is, at the same time, enjoyable for the reader. To do this, we must use the attributes that characterize good scientific style, with simple, clear, precise, direct, rigorous, and consistent language. Authorship implies authenticity and authority, and considering a researcher as an author entails rights and responsibilities. Scientific writing is not easy, it requires patience and practice; learning to write well is a lifelong task. With the philosophy that most of the qualities required to proficiently write a scientific article depend on attitude, and can be learned and improved upon, in this manuscript we will share with the reader a series of recommendations (based on our own experiences, both positive and negative), which we consider important for writing and successfully publishing. We will focus on the so-called «original» articles (as opposed to review articles, although many of the recommendations presented are applicable to both). Our main purpose is to encourage researchers to take the necessary step and face the challenge of becoming authors of their own scientific articles and successfully publishing their research.

科学在发表之前几乎不存在。只有这样,信息才能超越作者的局限,为科学界所共享。尽管科学文章必须遵循严格定义的结构,但仍有空间讲述一个引人入胜的故事,一个既能清晰传达科学知识,又能让读者愉悦的故事。要做到这一点,我们必须使用良好科学文体的特征,即简单、清晰、准确、直接、严谨和一致的语言。作者身份意味着真实性和权威性,将研究人员视为作者意味着权利和责任。科学写作并非易事,需要耐心和实践;学好写作是一项终身任务。本着熟练撰写科学文章所需的大部分素质都取决于态度,并且可以学习和提高的理念,我们将在本手稿中与读者分享一系列建议(基于我们自身的正反两方面经验),我们认为这些建议对于撰写文章并成功发表非常重要。我们将把重点放在所谓的 "原创 "文章上(与综述文章相对,尽管我们提出的许多建议对两者都适用)。我们的主要目的是鼓励研究人员迈出必要的一步,迎接挑战,成为自己科研文章的作者,并成功发表自己的研究成果。
{"title":"Tips and tricks for writing a manuscript to publish in a biomedical journal.","authors":"Javier P Gisbert, María Chaparro","doi":"10.1016/j.gastrohep.2024.502237","DOIUrl":"10.1016/j.gastrohep.2024.502237","url":null,"abstract":"<p><p>Science barely exists until it is published. It is only then that the information surpasses the limits of the author and can be shared by the scientific community. Although scientific articles must follow a rigidly defined structure, there is still room to tell a fascinating story, one that clearly conveys the science and is, at the same time, enjoyable for the reader. To do this, we must use the attributes that characterize good scientific style, with simple, clear, precise, direct, rigorous, and consistent language. Authorship implies authenticity and authority, and considering a researcher as an author entails rights and responsibilities. Scientific writing is not easy, it requires patience and practice; learning to write well is a lifelong task. With the philosophy that most of the qualities required to proficiently write a scientific article depend on attitude, and can be learned and improved upon, in this manuscript we will share with the reader a series of recommendations (based on our own experiences, both positive and negative), which we consider important for writing and successfully publishing. We will focus on the so-called «original» articles (as opposed to review articles, although many of the recommendations presented are applicable to both). Our main purpose is to encourage researchers to take the necessary step and face the challenge of becoming authors of their own scientific articles and successfully publishing their research.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small bowel Crohn's disease: Proximal lesions linked to increased inflammation and biologic treatment needs. 小肠克罗恩病:近端病变与炎症加重和生物治疗需求有关。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-05 DOI: 10.1016/j.gastrohep.2024.502235
João Carlos Gonçalves, Cátia Arieira, Sofia Xavier, Joana Magalhães, Maria João Moreira, Bruno Rosa, José Cotter

Objective: Crohn's disease (CD) is heterogeneous, and proximal involvement in the small bowel (SB) is associated with worse outcomes. Nonetheless, studies on the impact of duodenal and jejunal lesions in SB CD are limited. This study aimed to investigate the clinical characteristics and outcomes of individuals diagnosed with SB CD, comparing those with and without proximal inflammation.

Methods: A cohort of 53 treatment-naive SB CD patients that underwent Capsule Endoscopy at diagnosis were retrospectively selected. The inflammatory activity was quantified using the Lewis Score for each SB tertile.

Results: Thirty-seven (69.8%) patients displayed inflammatory activity in the first and/or second tertile together with third tertile involvement (Proximal+T3 group). Sixteen (30.2%) had inflammation in the third tertile only (T3 group). Individuals in the Proximal+T3 group had a higher risk for moderate-to-severe inflammation (OR 4.93, 95% CI: 1.3-18.3, p=0.013). A subgroup analysis for those with mild inflammatory activity showed that individuals in the Proximal+T3 group initiated biologic drugs more often (OR 11, 95% CI: 1.1-109.7, p=0.036).

Conclusion: Proximal SB lesions are associated with increased inflammatory activity, necessitating more frequent use of biologics in patients with mild disease. Early detection of proximal SB CD with Capsule Endoscopy may contribute to timely treatment.

目的:克罗恩病(CD)具有异质性,小肠(SB)近端受累与较差的预后有关。然而,有关十二指肠和空肠病变对克罗恩病(SB)影响的研究非常有限。本研究旨在调查被诊断为SB CD患者的临床特征和预后,并对有和没有近端炎症的患者进行比较:方法:回顾性选取了53名在诊断时接受了胶囊内镜检查、未经治疗的SB CD患者。结果:37 例(69.8%)SB CD 患者的近端炎症活动被量化:结果:37 例(69.8%)患者的炎症活动位于第一和/或第二梯度,同时受累于第三梯度(近端+T3 组)。16名患者(30.2%)仅在第三层出现炎症(T3组)。近端+T3组的患者出现中度至重度炎症的风险较高(OR 4.93,95% CI:1.3-18.3,P=0.013)。对轻度炎症活动者进行的亚组分析表明,近端+T3组患者更常开始使用生物药物(OR 11,95% CI:1.1-109.7,p=0.036):结论:SB近端病变与炎症活动增加有关,因此轻度患者需要更频繁地使用生物制剂。使用胶囊内镜及早发现SB近端CD可能有助于及时治疗。
{"title":"Small bowel Crohn's disease: Proximal lesions linked to increased inflammation and biologic treatment needs.","authors":"João Carlos Gonçalves, Cátia Arieira, Sofia Xavier, Joana Magalhães, Maria João Moreira, Bruno Rosa, José Cotter","doi":"10.1016/j.gastrohep.2024.502235","DOIUrl":"10.1016/j.gastrohep.2024.502235","url":null,"abstract":"<p><strong>Objective: </strong>Crohn's disease (CD) is heterogeneous, and proximal involvement in the small bowel (SB) is associated with worse outcomes. Nonetheless, studies on the impact of duodenal and jejunal lesions in SB CD are limited. This study aimed to investigate the clinical characteristics and outcomes of individuals diagnosed with SB CD, comparing those with and without proximal inflammation.</p><p><strong>Methods: </strong>A cohort of 53 treatment-naive SB CD patients that underwent Capsule Endoscopy at diagnosis were retrospectively selected. The inflammatory activity was quantified using the Lewis Score for each SB tertile.</p><p><strong>Results: </strong>Thirty-seven (69.8%) patients displayed inflammatory activity in the first and/or second tertile together with third tertile involvement (Proximal+T3 group). Sixteen (30.2%) had inflammation in the third tertile only (T3 group). Individuals in the Proximal+T3 group had a higher risk for moderate-to-severe inflammation (OR 4.93, 95% CI: 1.3-18.3, p=0.013). A subgroup analysis for those with mild inflammatory activity showed that individuals in the Proximal+T3 group initiated biologic drugs more often (OR 11, 95% CI: 1.1-109.7, p=0.036).</p><p><strong>Conclusion: </strong>Proximal SB lesions are associated with increased inflammatory activity, necessitating more frequent use of biologics in patients with mild disease. Early detection of proximal SB CD with Capsule Endoscopy may contribute to timely treatment.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An innovative steroid application for preventing esophageal stricture in patients undergoing circumferential endoscopic submucosal dissection. 在接受环形内镜黏膜下剥离术的患者中应用类固醇预防食管狭窄的创新方法。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-03 DOI: 10.1016/j.gastrohep.2024.502234
Yonghong Luo, Tingfa Peng, Bing Hu, Liansong Ye
{"title":"An innovative steroid application for preventing esophageal stricture in patients undergoing circumferential endoscopic submucosal dissection.","authors":"Yonghong Luo, Tingfa Peng, Bing Hu, Liansong Ye","doi":"10.1016/j.gastrohep.2024.502234","DOIUrl":"10.1016/j.gastrohep.2024.502234","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
¿Qué estrategias empleamos en la prevención y el seguimiento del virus del papiloma humano en pacientes con enfermedad inflamatoria intestinal? 我们在预防和监测炎症性肠病患者的人类乳头瘤病毒方面采取了哪些策略?
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-20 DOI: 10.1016/j.gastrohep.2024.04.005
{"title":"¿Qué estrategias empleamos en la prevención y el seguimiento del virus del papiloma humano en pacientes con enfermedad inflamatoria intestinal?","authors":"","doi":"10.1016/j.gastrohep.2024.04.005","DOIUrl":"10.1016/j.gastrohep.2024.04.005","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heterotaxy syndrome: When almost nothing is as it should be. 异位综合征:当几乎所有事情都不尽如人意时。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-17 DOI: 10.1016/j.gastrohep.2024.502233
Luisa Adán-Merino, Francisco Garrido Gallego, Rodrigo Pastorín-Salis, Ángel Ponferrada-Díaz
{"title":"Heterotaxy syndrome: When almost nothing is as it should be.","authors":"Luisa Adán-Merino, Francisco Garrido Gallego, Rodrigo Pastorín-Salis, Ángel Ponferrada-Díaz","doi":"10.1016/j.gastrohep.2024.502233","DOIUrl":"10.1016/j.gastrohep.2024.502233","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of response to a dietary intervention in patients with irritable bowel syndrome. 肠易激综合征患者对饮食干预反应的预测因素。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-17 DOI: 10.1016/j.gastrohep.2024.502231
Facundo Pereyra, Francisco Schlottmann, Carolina Salvatori, Sofía Barbagelata, Leandro Steinberg, Lisandro Pereyra

Background: Different diets have emerged as potential therapeutic options for patients with irritable bowel syndrome (IBS).

Objective: To identify predictors of improvement after a low-FODMAP, low-starch and low-sucrose diet among patients with IBS.

Methods: We performed a descriptive cross-sectional study including patients with IBS according to Rome IV criteria undertaking a social-media based program with a two-week dietary intervention. Patients completed an online survey before and after the intervention including the presence of intestinal and extra-intestinal symptoms, the IBS-SSS (irritable bowel syndrome symptoms severity scale) and the PHQ-9 (patient health questionnaire-9). Clinical improvement was defined as a decrease of at least 50% in IBS-SSS post dietary intervention. Variables associated with symptomatic response were identified with logistic regression analysis. A clinical score to predict response was created and tested with a with a receiver operating characteristic (ROC) curve analysis.

Results: A total of 3583 patients with IBS were included. Mean IBS-SSS before and after dietary intervention was 295.5±52.32 and 240±48.66, respectively (p=0.01); 1178 (32.8%) patients showed clinical improvement. A mean basal IBS-SSS >400 (OR 3.04), chronic headache (OR 1.96), and chronic fatigue (OR 1.81) were significantly associated with symptomatic response. Patients with arthralgia (OR 0.41) and/or fibromyalgia (OR 0.33) were less likely to improve. Each variable received the following individuals scores: IBS-SSS >400: +2, chronic headache: +1.5, chronic fatigue: +1, arthralgia: -1, and fibromyalgia: -1. The ROC curve analysis of the proposed score showed an area under the curve of 0.72 (95% CI 0.69-0.76). A score ≥3 had a sensitivity of 72.64% and specificity of 60.56% for predicting symptomatic improvement.

Conclusions: There are clinical variables that could serve as reliable predictors of response to a low-FODMAP, low-sucrose, low-starch diet among patients with IBS. Further research is needed to understand the link between the presence of extra-intestinal symptoms and clinical improvement after dietary interventions for IBS.

背景:不同的饮食已成为肠易激综合征(IBS)患者的潜在治疗方案:目的:确定肠易激综合征患者采用低 FODMAP、低淀粉和低蔗糖饮食后病情改善的预测因素:我们进行了一项描述性横断面研究,研究对象包括符合罗马IV标准的肠易激综合征患者,他们接受了一项基于社交媒体的计划,并进行了为期两周的饮食干预。患者在干预前后完成了一项在线调查,内容包括肠道和肠道外症状、IBS-SSS(肠易激综合征症状严重程度量表)和 PHQ-9(患者健康问卷-9)。饮食干预后 IBS-SSS 至少减少 50%,即为临床症状改善。通过逻辑回归分析确定了与症状反应相关的变量。建立了预测反应的临床评分,并通过接收者操作特征曲线(ROC)分析进行了测试:共纳入 3,583 名肠易激综合征患者。饮食干预前后的 IBS-SSS 平均值分别为 295.5 ± 52.32 和 240 ± 48.66(P=0.01);1178 名(32.8%)患者的临床症状有所改善。平均基础 IBS-SSS > 400(OR 3.04)、慢性头痛(OR 1.96)和慢性疲劳(OR 1.81)与症状反应显著相关。患有关节痛(OR 0.41)和/或纤维肌痛(OR 0.33)的患者症状改善的可能性较小。每个变量的个体得分如下IBS-SSS > 400:+2,慢性头痛:+1.5,慢性疲劳:+1.5:+1.5,慢性疲劳+拟议评分的 ROC 曲线分析显示曲线下面积为 0.72(95%CI 0.69-0.76)。在预测症状改善方面,得分≥3 的灵敏度为 72.64%,特异度为 60.56%:有一些临床变量可以作为肠易激综合征患者对低-FODMAP、低蔗糖、低淀粉饮食反应的可靠预测指标。要了解肠道外症状的存在与肠易激综合征饮食干预后临床症状改善之间的联系,还需要进一步的研究。
{"title":"Predictors of response to a dietary intervention in patients with irritable bowel syndrome.","authors":"Facundo Pereyra, Francisco Schlottmann, Carolina Salvatori, Sofía Barbagelata, Leandro Steinberg, Lisandro Pereyra","doi":"10.1016/j.gastrohep.2024.502231","DOIUrl":"10.1016/j.gastrohep.2024.502231","url":null,"abstract":"<p><strong>Background: </strong>Different diets have emerged as potential therapeutic options for patients with irritable bowel syndrome (IBS).</p><p><strong>Objective: </strong>To identify predictors of improvement after a low-FODMAP, low-starch and low-sucrose diet among patients with IBS.</p><p><strong>Methods: </strong>We performed a descriptive cross-sectional study including patients with IBS according to Rome IV criteria undertaking a social-media based program with a two-week dietary intervention. Patients completed an online survey before and after the intervention including the presence of intestinal and extra-intestinal symptoms, the IBS-SSS (irritable bowel syndrome symptoms severity scale) and the PHQ-9 (patient health questionnaire-9). Clinical improvement was defined as a decrease of at least 50% in IBS-SSS post dietary intervention. Variables associated with symptomatic response were identified with logistic regression analysis. A clinical score to predict response was created and tested with a with a receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>A total of 3583 patients with IBS were included. Mean IBS-SSS before and after dietary intervention was 295.5±52.32 and 240±48.66, respectively (p=0.01); 1178 (32.8%) patients showed clinical improvement. A mean basal IBS-SSS >400 (OR 3.04), chronic headache (OR 1.96), and chronic fatigue (OR 1.81) were significantly associated with symptomatic response. Patients with arthralgia (OR 0.41) and/or fibromyalgia (OR 0.33) were less likely to improve. Each variable received the following individuals scores: IBS-SSS >400: +2, chronic headache: +1.5, chronic fatigue: +1, arthralgia: -1, and fibromyalgia: -1. The ROC curve analysis of the proposed score showed an area under the curve of 0.72 (95% CI 0.69-0.76). A score ≥3 had a sensitivity of 72.64% and specificity of 60.56% for predicting symptomatic improvement.</p><p><strong>Conclusions: </strong>There are clinical variables that could serve as reliable predictors of response to a low-FODMAP, low-sucrose, low-starch diet among patients with IBS. Further research is needed to understand the link between the presence of extra-intestinal symptoms and clinical improvement after dietary interventions for IBS.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gastroenterologia y hepatologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1